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Marta Kutwin1, Ewa Sawosz1, Sławomir Jaworski1, Natalia Kurantowicz1, Barbara Strojny1 and André Chwalibog2*Abstract
Side effects and resistance of cancer cells to cisplatin are major drawbacks to its application, and recently, the
possibility of replacing cisplatin with nanocompounds has been considered. Most chemotherapeutic agents are
administered intravenously, and comparisons between the interactions of platinum nanoparticles (NP-Pt) and
cisplatin with blood compartments are important for future applications. This study investigated structural damage,
cell membrane deformation and haemolysis of chicken embryo red blood cells (RBC) after treatment with cisplatin
and NP-Pt. Cisplatin (4 μg/ml) and NP-Pt (2,6 μg/ml), when incubated with chicken embryo RBC, were detrimental
to cell structure and induced haemolysis. The level of haemolytic injury was increased after cisplatin and NP-Pt
treatments compared to the control group. Treatment with cisplatin caused structural damage to cell membranes
and the appearance of keratocytes, while NP-Pt caused cell membrane deformations (discoid shape of cells was
lost) and the formation of knizocytes and echinocytes. This work demonstrated that NP-Pt have potential
applications in anticancer therapy, but potential toxic side effects must be explored in future preclinical research.
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Cisplatin (cis-diamineplatinum(II) dichloride) is a che-
motherapeutic drug widely used against various solid tu-
mours and testicular cancer, which has dose-dependent
side effects like nephrotoxicity, emetogenesis, ototoxicity,
neurotoxicity and haemolysis [1-3]. Repeated intravenous
administration of platinum salts may induce haemolytic
anaemia by interfering with iron metabolism, decreasing
the level of red blood cell precursors and creating an
immune-complex between red blood cells (RBC) and
cisplatin [4,5]. Moreover, side effects, including haemo-
lytic properties, and resistance of cancer cells to cisplatin
are major drawbacks to its application in cancer therapy,
and recently, the possibility of replacing platinum salts
with nanocompounds has been considered [6-8]. Due to
their size (<25 nm), large surface to mass ratio, quantum
properties, catalytic activity and high reactivity, platinum
nanoparticles (NP-Pt) have unique physicochemical prop-
erties and can exert specific effects on a living organism.
The bioavailability of NP-Pt colloids depends on particle* Correspondence: ach@sund.ku.dk
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in any medium, provided the original work is psize, and small NP-Pt (<4 nm) were more barcterio-toxic
[9], induced the human cell genotoxic stress (5 to 8 nm)
[10] and activated the cell death by apoptosis [11] com-
pared to the bigger nanoparticles (>100 nm) [12,13]. NP-
Pt can cause cell cycle arrest and activate apoptosis
through the release of Pt2+ ions during H2O2 generation
due to the low pH in endosomes [14], and DNA double-
strand breaks are caused by Pt2+ ions when NP-Pt are in-
cubated with human colon carcinoma cells (HT29) [15].
However, the consequences of in vivo NP-Pt administra-
tion are not well documented and must be elucidated in
future research [9].
Haemolytic properties and interactions with RBC are
main parameters for the biocompatibility of nanoparticles
[5,16]. The bloodstream is the main translocation path
for glucose, oxygen and carbon dioxide, as well as nano-
particles. Incubation of silver (Ag), gold (Au) and Pt nano-
particles with human RBC demonstrated that Au and Pt
nanoparticles are non-haemolytic but cause haemagglutin-
ation, while Ag nanoparticles are haemolytic [14]. In vitro
haemocompatibility studies indicated that biosynthesised
Pt nanoparticles had negligible haemolytic effects [17],
while Ashranani et al. reported that Pt and Au nanoparti-
cles (compared to Ag) were more haemocompatible andan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Kutwin et al. Nanoscale Research Letters 2014, 9:257 Page 2 of 6
http://www.nanoscalereslett.com/content/9/1/257did not show the agglutination of erythrocyte and also no
precipitation properties [14]. On the other hand, Ag nano-
particles did not cause significant changes in micronu-
cleated polychromic erythrocytes, and no dose-dependent
differences in haemolysis were observed [3]. Recent stud-
ies have demonstrated the haemolytic properties of other
nanoparticles like polystyrene [18], PLGA [4], TiO2 [19]
and mesoporous silica [20].
This study evaluated the hypothesis that NP-Pt may
affect the morphology of chicken embryo RBC, causing
haemolysis and structural damage comparable to Pt salt.
The objective of this preliminary work was to compare
the biocompatibility of NP-Pt and cisplatin with chicken
embryo RBC.
Methods
Hydrocolloids
NP-Pt hydrocolloid was obtained from Nano-koloid
(Warsaw, Poland), which was produced by a patented
electric non-explosive method (Polish patent 380649)
from high-purity metal (99.9999%) and high-purity demi-
neralized water, and diluted to 2.6 μg/ml in phosphate
buffered saline (PBS: pH 7.2; P4417, Sigma-Aldrich, St.
Louis, MO, USA).
The morphology of NP-Pt was inspected using a JEOL
JEM-1220 transmission electron microscope (TEM, JEOL
Ltd., Tokyo, Japan) at 80 KeV equipped with a Morada 11
megapixel camera (Olympus Corporation, Tokyo, Japan)
(Figure 1). Triplicate samples of NP-Pt were prepared for
TEM by placing droplets of the hydrocolloid onto
Formvar-coated copper grids (Agar Scientific Ltd., Stansted,
UK) and air drying before TEM imaging (Figure 1). The
zeta potential of the NP-Pt hydrocolloid was measured
by the electrophoretic light-scattering method using a
Zetasizer Nano-ZS90 (Malvern, Worcestershire, UK).Figure 1 TEM imagines of platinum nanoparticles. Scale bar,
100 nm.Each sample (20 replicates) of NP-Pt was measured
after 120 s of stabilization at 25°C.
Cisplatin (cis-diamineplatinum(II) dichloride) was ob-
tain from Sigma (479306; Sigma, St. Louis, MO, USA)
and diluted to 4 μg/ml in PBS immediately before use.
The final concentration of cisplatin hydrocolloid was
4 μg/ml of cisplatin, because of the potential and the
best efficiency (67% of mice tumour free after 4 μg/ml
cisplatin treatment) for intratumoural injection [1]. The
concentration of NP-Pt (2.6 μg/ml) was equal to the
atomic mass of Pt atoms in cisplatin.
Embryo model
Fertilized eggs (n = 20; 56 ± 2.2 g) from Ross Line hens
were obtained from a commercial hatchery, stored at 12°C
for 4 days and incubated under standard conditions for an
additional 19 days (temperature 37.5°C, 60% humidity,
turning once per hour). On day 20, the embryos were
sacrificed by decapitation and blood samples (one sample
from each embryo) collected from the jugular vein. Blood
samples were divided into four groups: control untreated
(0% haemolysis), positive control treated with 3% hydro-
gen peroxide (100% haemolysis), 4 μg/ml cisplatin [1] and
2.6 μg/ml NP-Pt hydrocolloid diluted in PBS. The samples
were placed in Vacutainer tubes (BD Inc., Franklin
Lakes, NJ, USA) containing ethylenediaminetetraacetic
acid (EDTA), gently mixed on a rotary shaker and incu-
bated for 3 h at 37°C. The incubation time was based on
the research publications [14,21] and an adjustment of
the standard ASTM F-756-00 [22].
All measurements were performed in three repetitions
(each experimental group in triplicate).
Blood cell morphology
Light microscopy
Peripheral blood smears were made using 5 μl of
blood, air-dried and stained by May-Grünwald-Giemsa.
Peripheral blood smears were examined at × 1,000 mag-
nification (Leica DM750, Leica Microsystems, Nussloch,
Germany).
Scanning electron microscopy
Scanning electron microscopy (SEM) analysis of RBC
was performed by means of an FEI Quanta 200 electron
microscope (FEI Co., Hillsboro, OR, USA). The blood
samples were rinsed in PBS (0.01 M, pH 7.2; P4417,
Sigma) then fixed in 2.5% glutaraldehyde (G5882, Sigma)
for 1 h, washed twice in 0.1 M PBS (0,01 M, pH 7.2;
P4417, Sigma) and placed on aluminium SEM stubs.
The SEM stubs were kept in a moist atmosphere for 1 h,
washed in PBS (0.01 M, pH 7.2; P4417, Sigma), post-
fixed in 1% osmium tetroxide (75632, Sigma) for 1 h,
rinsed in distilled water and dehydrated in graded etha-
nols. After critical point drying with liquid CO2 in a
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nologies, Newhaven, East Sussex, UK) and coating with
gold-palladium (JEE-4C, JEOL Ltd., Tokyo, Japan),
the samples were inspected by SEM at 1 KeV (FEI
Quanta 200).
Haemolytic assay
The haemolysis assay was performed with chicken whole
blood. After incubation, the tubes containing blood sam-
ples from the groups - control untreated (0% haemolysis),
positive control treated with 3% hydrogen peroxide (100%
haemolysis), 4 μg/ml cisplatin [1] and 2.6 μg/ml NP-Pt
hydrocolloid - were centrifuged at 1,200 rpm (Sorvall ST
16, Thermo Fisher Scientific, Waltham, USA) for 10 min
to collect the plasma. The supernatant was analysed for
the presence of the haemoglobin at 540 nm (Infinite
M200, Tecan, Durham, NC, USA) and percent haemolysis
calculated according to Shiny et al. [17].
Statistical analysis
The data was evaluated by mono-factorial analysis of vari-
ance (ANOVA). The differences between groups were
tested by the multiple-range Tukey test using Statgraphic
Centurion ver. XV (Statpoint Technologies, Warrenton,
VO, USA). Differences with P < 0.05 were considered
significant.
Results
Nanoparticles
TEM observation of NP-Pt did show that NP-Pt had
regular spherical shape ranging from 2 to 19 nm, and
also the aggregation of nanoparticles was not observed
(Figure 1). The mean zeta potential of the NP-Pt
was −9.6 mV.
Evaluation of morphological changes by microscopy
Evaluation of RBC by light microscopy demonstrated that
NP-Pt and cisplatin had harmful effects on morphology.
The cell membranes were damaged, the shape of cells wasFigure 2 RBC morphology by light microscopy. (A) Control (without tre
erythrocytes; white arrow, swollen RBC; g, ghost cells. Scale bar, 20 μm.deformed and cells lost their biconcavity. Observation also
showed an increasing level of swollen cells as a result of
membrane damage after osmotic pressure on red blood
cells (Figure 2). Exposure of RBC to NP-Pt and cisplatin
caused haemagglutination. Scanning electron microscopy
revealed ruffled cells, membrane deformations and loss
of the discoid shape of RBC treated with NP-Pt. After
cisplatin treatment, keratocytes were seen (Figure 3B),
indicating that cisplatin had haemolytic properties.
After NP-Pt treatment (Figure 3C), there were struc-
tural changes in the RBC, and knizocytes were also
seen. SEM analysis of RBC treated with NP-Pt also
showed early echinocytes with blebs and protuberances
on their surfaces.
Haemolysis
NP-Pt and cisplatin were haemolytic compared to the
control group (Figure 4), and the percent haemolysis
was higher for NP-Pt (23%) than for cisplatin (14%). The
lack of haemolysis in the control group and almost 100%
haemolysis in the positive control group (treated with
3% hydrogen peroxide) confirmed the accuracy of the
assay.
Discussion
Chicken embryo RBC were exposed to NP-Pt and the
antineoplastic drug cisplatin, which allowed haemocom-
patibility to be evaluated in a short time, as well as serving
as a fast, precise model for evaluating toxicity [11,23,24]. It
has been demonstrated that NP-Pt had harmful effects on
in vivo mice model, causing kidney injury after intraven-
ous administration [25] and inflammatory responses after
intratracheal instillation [26]. Furthermore, NP-Pt had
harmful effect on in ovo model, causing mitochondria
degradation at chicken embryo brain tissue ultrastruc-
ture, activation of apoptosis and reduced proliferation
rate of the brain cells [11]. In the present research, NP-
Pt at 2.6 μg/ml incubated with whole chicken blood af-
fected RBC morphology and haemocompatibility status.atment), (B) cisplatin and (C) NP-Pt. Black arrow, deformation of
A B C
Figure 3 Visualization of RBC morphology by scanning electron microscopy. (A) Control (without treatment), (B) cisplatin and (C) NP-Pt.
Asterisk, keratocyte; k, knizocyte; e, echinocyte. Scale bar, 10 μm.
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structures, there were substantial differences between
NP-Pt and cisplatin. The RBC treated with NP-Pt lost
their biconcavity and showed corrugations and damage
to cell membranes. The analysis of peripheral blood
smears from the NP-Pt group revealed the presence of
ghost cells, which are the result of cell lysis and release
of haemoglobin from RBC [27]. On the other hand,
other studies did not show any harmful effect on human
RBC structure [21].
The haemolytic properties of Pt drugs during chemo-
therapy are also responsible for higher risks of blood
diseases like anaemia [28]. Comparing the results of this
study with previous reports on the haemocompatibility
of cisplatin confirmed the haemolytic activity of Pt-
based drugs as one of the main side effects causing
haemolytic anaemia and also bone marrow diseases and
haemolysis [2,29]. The present results demonstrated
that both cisplatin and NP-Pt induced haemolysis com-
pared to the control group. Evaluation of haemocom-
patibility of nanoparticles should be considered as one
of the factors of assessing systemic toxicity. HaemolyticFigure 4 Haemolysis of RBC. Bars with different superscripts denote a sta
and groups treated with the following: 3% hydrogen peroxide (positive co
error of the mean. The bars with different letters indicate significant differeproperties of the nanoparticles can be determined by
spectrophotometric measurement (540 nm) and based
on adjustments of the ASTM F-756-00 standard [22].
Human RBC have different morphology than chicken
RBC, with the primary difference being that chicken
RBC have a nucleus containing genetic material. The
mechanism of action for platinum-containing anticancer
drug utilizes the presence of DNA to induce cancer cell
death by apoptosis [30,31]. Regarding the antineoplastic
properties of ciplatin, it is important to emphasize that
the intravenous administration of cisplatin has severe
side effect on blood compartments. The present results
confirmed that cisplatin and NP-Pt not only induced
haemolysis but also caused the structural damage of
RBC. Haemolytic as well as toxic properties of nanopar-
ticles can be reduced by increasing the particle size [12]
or by excluding intravenous administration.
Haemocompatibility studies of Pt, Au and Ag nano-
particles demonstrated that only Ag has harmful effects
on the structure of human RBC and significantly affected
haemolytic status [14]. On the other hand, NP-Pt were de-
scribed as haemocompatible materials [21]. Furthermore,tistically significant difference between the control group (untreated)
ntrol), cisplatin (4 μg/ml) or NP-Pt (2.6 μg/ml). Error bars are standard
nces, P < 0.05.
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NP-Pt have minor effects on cell membrane structure but
still cause haemolysis [17]. The present results revealed
that cisplatin treatment led to formation of keratocytes,
indicating that cisplatin was haemolytic, which may be
due to mechanical fragility or oxidant injury to RBC
[32]. The results also showed that NP-Pt treatment
caused the damage of RBC and also appearance of kni-
zocytes. Knizocytes are RBC with multiple concavities
due to indentations of the cell membrane, observed in
newborn mammals as a young type of RBC with cell
membrane deformations, and also their appearance indi-
cates an impaired microcirculation or impaired oxygen-
carrying capacity [33] SEM analysis revealed that after
NP-Pt treatment, early echinocytes were observed which
may indicate harmful effects to RBC and a side effect often
associated with haemolytic anaemia [32,33].
The present results indicated that the percent haemoly-
sis after NP-Pt treatment was higher compared to cisplatin
treatment. These finding may indicate that NP-Pt were
toxic to RBC by direct interactions with 2.4 pg of genetic
material in chicken RBC [34]. Furthermore, chicken nu-
clear DNA has a 42% to 43% guanine and cytosine base-
pair content [35] which is acted upon by cisplatin, where
guanine bases (especially the N7 sites) are preferred sites
for Pt binding to DNA [36]. Damage of RBC under the
influence of NP-Pt probably was related to the ability to
arrest the cell cycle and also the cytotoxicity of NP-Pt
[6,10,37]. These mechanisms may be responsible for the
pathomorphological changes in chicken RBC and also
for a high occurrence of haemolysis.
Conclusions
NP-Pt and cisplatin incubated with chicken embryo RBC
caused damage to the structure of RBC and induced
haemolysis. Treatment with cisplatin caused structural
damage to cell membranes and the appearance of kera-
tocytes, while NP-Pt caused cell membrane deformation,
loss of the discoid shape and the formation of knizocytes
and echinocytes. These preliminary results indicated that
NP-Pt could be utilized for cancer therapy instead of
cisplatin, but potential side effects must be evaluated in
future research.
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